Please assess the completion status of the following clinical trial:

Trial Title: Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and females, 18 to 55 years of age (inclusive) at the time of screening.~* Subjects must be in good general health, with no significant medical history (including migraine), have no clinically significant abnormalities on physical examination at screening, and/or before administration of the initial dose of investigational product.~* Subjects must have a Body Mass Index (BMI) between 18 and 32 kg/m2, inclusive.~* Subjects must have clinical laboratory values within normal range as specified by the testing laboratory, or assessed as not clinically significant by the Principal Investigator.~* Negative urine drug screen/alcohol breath test at screening.~* Subjects who are willing to refrain from smoking for the duration of the study.~Exclusion Criteria:~* Subjects with a recent history of migraine and its variants including hemiplegic migraine and basilar migraine. A recent history of migraine is defined as (a) current or past history of migraine with at least 1 attack in last 6 months or (b) those receiving antimigraine prophylaxis.~* Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV).~* Subjects who have ingested caffeine within 48 hours before admission on Day -1. Subjects must also agree to refrain from consumption of caffeinated drinks for 48 hours before admission of Days 7 and 14 (i.e. prior to each subsequent dosing), and throughout confinement.~* Subjects with ischemic heart disease or subjects who have clinical symptoms or findings consistent with coronary artery vasospasm including Prinzmetal's variant angina.~* Subjects with hypertension, known peripheral arterial disease, Raynaud's phenomenon, sepsis, history of vascular surgery or severely impaired hepatic or renal function~* Subjects who have previously shown hypersensitivity to ergot alkaloids or metoclopramide.~* Use of any relevant prescription, over-the-counter medication (with the exception of oral contraceptives), foods (e.g. grapefruit juice) or supplements (including herbal) within 14 days of randomization \[especially those affecting the Cytochrome P450 3A4 (CYP3A4) metabolic pathway\].~* History or presence of alcoholism or drug abuse within the 2 years prior to the first investigational product administration.~* Surgery within the past three months prior to the first investigational product administration as determined by the PI to be clinically relevant.~* Active infection and/or use of macrolide antibiotics within 14 days prior to enrollment.~* History of recurrent infections.~* Any nasal congestion or physical blockage in either nostril, or deviated nasal septum as determined by nasal examination.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- INP104 (Type: EXPERIMENTAL): Single dose 1.45 mg Dihydroergotamine Mesylate (DHE), administered by I123 Precision Olfactory Delivery (POD) device nasal spray (INP104)
- D.H.E. 45 Injection (IV) (Type: ACTIVE_COMPARATOR): Single dose 1 mg Dihydroergotamine Mesylate (DHE) for intravenous injection
- Migranal Nasal Spray (Type: ACTIVE_COMPARATOR): Single dose 2 mg Migranal Nasal Spray Dihydroergotamine Mesylate (DHE)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete